CJASN
@CJASN
The leading voice for the latest advancements in clinical nephrology. Official publication of @ASNKidney. Impact Factor 9.8.
ID:2773651974
http://cjasn.asnjournals.org/ 27-08-2014 16:02:37
3,6K Tweet
27,7K Takipçi
1,1K Takip Edilen
Follow People
COVID-19 has posed increased risks of hospitalization and mortality in patients with CKD. This study found a relationship between the number of vaccine doses & effectiveness against COVID-19 infection & comorbidity bit.ly/CJASN0376
Esther Chan @ CSMPR HKU Francisco TT Lai
'...the kidney transplant community must always strive to improve support and care of living kidney donors throughout their postdonation journey.' In this Patient Voice article, Kevin J. Fowler Principal The Voice of the Patient highlights potential to advance living donor safety bit.ly/CJASN0446
Iron deficiency is common in children with kidney failure, but guidelines are based on biomarkers of iron stores that may be influenced by inflammation. This study found serum ferritin provided the best indication of stainable marrow iron stores bit.ly/CJASN0469
Mark Hanudel
Children with rare kidney diseases have serious morbidity and require lifelong treatment. This article highlights the unique challenges encountered in managing these diseases in under-resourced settings bit.ly/CJASN0374
Priya Pais
Community-acquired AKI is a common but under-recognized condition developed outside of the hospital. This study evaluated outpatient nephrology care ≤90 days after an episode of community-acquired AKI bit.ly/CJASN0448
Clarissa Diamantidis C. Barrett Bowling
'The two most extensive trials evaluating cardiovascular outcomes in patients receiving sotagliflozin include the SOLOIST-WHF and SCORED trials.' This Editorial discusses a recent exploratory analysis of the SCORED trial bit.ly/CJASN0465
george bakris
The American Society of Nephrology Journal editors recently created a new ASN Journals’ Editorial Board. This broader editorial board includes editors who work across all three journals to support JASN, CJASN, and American Society of Nephrology360. For more information, visit bit.ly/ASNEdBoard
SGLT2 inhibitors reduce the risk of cardiovascular disease in patients with CKD. This study found SGLT2 inhibitors reduced risk of cardiovascular death, having the most pronounced effects on risk of deaths attributed to heart failure bit.ly/CJASN0470
David C Wheeler